Save time and get answers to complex questions with AI chat
Regulatory challenges in the latin american generic drug market drugpatentwatch transform data into market domination?What excipients are combined with ruxolitinib in apotex's medication?Symbravo ingredients mechanism of action?Does lipitor's effectiveness decrease with high fat meals?When will tenofovir alafenide come off patent in canada?
See the DrugPatentWatch profile for Gilenya
Gilenya (fingolimod) is manufactured and marketed by Novartis.
The active ingredient is the same (fingolimod), but the marketed product holder can vary by country due to local licensing and distribution arrangements. In most markets, Novartis is the company associated with the product.
Gilenya’s generic name is fingolimod. That matters because different companies may manufacture generic fingolimod products if/when biosimilar or generic alternatives are approved and marketed in a specific region, even though the original brand is tied to Novartis.
For manufacturer and patent/exclusivity details tied to fingolimod (brand and generic competition landscape), DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/
Other Questions About Gilenya :